How to Get Tresiba (Insulin Degludec) in South Dakota

What Is Tresiba and Why It Matters for South Dakota Patients

Insulin degludec (brand name Tresiba) is an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours, giving it the longest pharmacokinetic profile of any commercially available insulin [1]. For South Dakota patients managing type 1 or type 2 diabetes, that prolonged action translates to a flatter, more stable glucose baseline than older basal insulins such as glargine U-100 or detemir.

The DEVOTE trial (N=7,637, NEJM 2017) compared insulin degludec with insulin glargine U-100 in patients with type 2 diabetes at high cardiovascular risk [2]. Degludec produced a 40% lower rate of severe nocturnal hypoglycemia than glargine (rate ratio 0.60; 95% CI 0.48 to 0.76; P<0.001) [2]. That finding is clinically meaningful for rural South Dakota patients who may live far from an emergency room.

The FDA approved Tresiba in September 2015 for adults with type 1 and type 2 diabetes, later expanding the label to include pediatric patients aged one year and older [3]. Dosing starts at 10 units once daily for insulin-naive type 2 patients or at the same unit dose replacing another basal insulin for established patients, titrated in 2-unit increments every three to four days targeting a fasting glucose of 80 to 130 mg/dL per American Diabetes Association (ADA) Standards of Care [4].

South Dakota has fewer than 15 board-certified endocrinologists practicing in the state according to state licensing data, making telehealth a practical access route for patients in Sioux Falls, Rapid City, and especially rural counties such as Tripp, Corson, or Haakon [5].

Labs Required Before Tresiba Is Prescribed in South Dakota

Most prescribers, whether in-person or telehealth, require four core labs before writing an insulin degludec prescription: HbA1c, fasting plasma glucose, a basic metabolic panel (BMP), and body weight. Ordering these through a local LabCorp, Sanford Health, or Avera draw station before a telehealth appointment cuts appointment time significantly.

HbA1c confirms the diagnosis and establishes severity. The ADA defines a diabetes diagnosis at HbA1c 6.5% or above on two separate occasions or a single value in the setting of classic hyperglycemic symptoms [4]. The BMP screens for renal function because impaired kidney clearance alters insulin sensitivity and affects dosing decisions. An eGFR <30 mL/min/1.73 m² may prompt lower starting doses and more frequent titration checks [6].

Thyroid function (TSH) is not always required but is commonly ordered in type 1 patients since autoimmune thyroid disease co-occurs in roughly 17 to 30% of type 1 diabetics [7]. C-peptide and GAD-65 antibody testing may be requested if the prescriber needs to distinguish type 1 from latent autoimmune diabetes in adults (LADA) before committing to basal-only therapy versus a basal-bolus regimen [8].

Completing labs in advance also accelerates prior authorization. South Dakota commercial insurers typically request a current HbA1c (within 90 days), documentation of prior basal insulin failure or intolerance, and the prescriber's clinical rationale before approving Tresiba. Gathering these before the appointment rather than after saves one to three weeks of approval time.

Continuous glucose monitoring (CGM) data, if available, can substitute for fasting glucose logs and often strengthens a prior authorization appeal by showing documented nocturnal hypoglycemia on a less expensive basal insulin. The Endocrine Society's 2022 guidelines on CGM use in insulin-treated diabetes support CGM data as objective evidence for formulary exception requests [9].

How to Get a Tresiba Prescription Through Telehealth in South Dakota

Telehealth prescribing of Tresiba is fully legal in South Dakota. State law allows licensed physicians, nurse practitioners, and physician assistants to conduct synchronous video visits and prescribe Schedule V and non-scheduled medications, including non-controlled basal insulins, across state lines when they hold South Dakota licensure or qualify under interstate compact agreements [10].

The practical steps are straightforward. A patient books a video visit with a South Dakota-licensed provider, uploads recent lab results and a list of current medications, and completes the visit. If the clinical criteria are met, the provider sends the prescription electronically to the patient's pharmacy of choice, including mail-order and specialty pharmacies that ship to South Dakota addresses.

South Dakota participates in the Interstate Medical Licensure Compact (IMLC), which allows physicians licensed in member states to obtain South Dakota prescribing authority without a full separate application [10]. The Nurse Licensure Compact (NLC) similarly allows NPs licensed in compact states to practice in South Dakota. That means a patient in Mobridge or Winner can see a diabetes-specialized NP based in Minnesota or Iowa via video and receive a legitimate South Dakota prescription.

Telehealth platforms typically complete the full visit-to-prescription workflow in 24 to 72 hours. Synchronous video is generally required for a first insulin prescription; asynchronous (store-and-forward) messaging alone is not sufficient for most South Dakota-licensed providers writing a new basal insulin order. Refills may proceed asynchronously if the prescriber-patient relationship is established.

The FDA's December 2020 guidance on telehealth prescribing clarified that non-controlled medications, including all insulin products, may be prescribed after a good-faith online evaluation that includes a review of medical history, current medications, and relevant labs [11]. Tresiba falls squarely within that category.

Who Can Prescribe Tresiba in South Dakota

South Dakota grants prescriptive authority for insulin degludec to physicians (MD, DO), nurse practitioners (NP) with a collaborative agreement or independent practice status, and physician assistants (PA) under a supervision agreement [12]. Pharmacists in South Dakota do not hold independent insulin prescribing authority but may adjust doses under a collaborative drug therapy agreement with a physician [12].

South Dakota NPs with a current license and a completed pharmacology training requirement may prescribe independently without a physician collaborator once they have practiced for two years and 2 to 080 hours under supervision [12]. That means a patient who cannot reach a physician in a rural area may access care from an NP-run telehealth clinic without any physician co-signature on the Tresiba prescription.

Physician assistants must have a supervision agreement on file with a South Dakota physician, but the supervising physician does not need to physically co-sign each prescription. Electronic supervision protocols are accepted, making PA-driven telehealth visits a viable access pathway for Tresiba prescriptions [12].

The prescriber's DEA number is not needed for insulin degludec since it is not a controlled substance. Licensure verification can be confirmed through the South Dakota Board of Medical and Osteopathic Examiners (for MDs and DOs) and the South Dakota Board of Nursing (for NPs) [13].

Tresiba Pharmacy Access in South Dakota: Retail, Mail-Order, and 503A Options

South Dakota retail pharmacies that stock Tresiba include major chains such as Walgreens, CVS, and Walmart, as well as regional independents affiliated with Sanford Health and Avera pharmacies. Availability varies by location. A Tresiba FlexTouch pen (100 units/mL, 3 mL cartridge) has a list price of approximately $530 per pen without insurance as of 2025, though this figure changes with formulary negotiations [14].

Mail-order pharmacies such as Express Scripts, OptumRx, and CVS Caremark ship Tresiba to South Dakota addresses. Typical shipping time is three to seven business days with cold-chain packaging. Patients should confirm that the pharmacy uses insulated packaging with ice packs rated for at least 48 hours, since South Dakota summer temperatures can exceed 100 degrees Fahrenheit and compromise insulin potency if packaging fails [15].

503A compounding pharmacies licensed in South Dakota may prepare insulin degludec formulations for individual patients with a valid prescription. 503A compounding is patient-specific, meaning the pharmacy fills only a prescription written for a named patient, not a batch product [16]. The FDA's oversight of 503A pharmacies does not alter the legal requirement for a valid prescriber-patient relationship before compounding [16]. Patients interested in compounded insulin should confirm that the 503A pharmacy holds a South Dakota Board of Pharmacy license and that the compounding rationale is documented in the patient's chart.

Novo Nordisk's Patient Assistance Program (PAP) offers Tresiba at no cost to uninsured patients meeting income criteria (generally at or below 400% of the federal poverty level) [17]. The My$99Insulin program from Novo Nordisk caps out-of-pocket cost at $99 per month for commercially insured patients who do not meet PAP income criteria [17]. Both programs are accessible to South Dakota residents.

Prior Authorization for Tresiba in South Dakota: What Documentation Is Required

Most South Dakota commercial plans and Medicare Part D plans require prior authorization before covering Tresiba because it sits on a non-preferred tier relative to insulin glargine biosimilars. The documentation checklist below covers what insurers consistently request.

First, the prescriber must provide a current HbA1c result from within the past 90 days. Second, the insurer needs evidence of at least one prior basal insulin trial, typically glargine or detemir for 90 days or more, with documentation of inadequate glycemic control or clinically significant hypoglycemia. Third, the prescriber supplies a letter of medical necessity citing the DEVOTE trial data on nocturnal hypoglycemia reduction and explaining why the patient requires degludec specifically [2].

South Dakota Medicaid does not cover Tresiba as of 2025, which means Medicaid patients must use an alternative basal insulin on the SD Medicaid preferred drug list or seek manufacturer assistance [18]. Medicaid recipients who believe Tresiba is medically necessary may file a prior authorization appeal through the South Dakota Department of Social Services, though approval rates for non-preferred insulins under Medicaid are low without documented allergy or intolerance to covered alternatives [18].

The American Diabetes Association's 2024 Standards of Care state directly: "Insulin degludec has demonstrated a lower risk of hypoglycemia compared with insulin glargine U-100 and may be preferred when hypoglycemia is a barrier to insulin intensification" [4]. Quoting this guideline language verbatim in a prior authorization letter often carries more weight than a prescriber's narrative alone.

Appeals that are denied at the first level may proceed to an external review through South Dakota's Division of Insurance, which mandates that insurers respond to urgent medication appeals within 72 hours [19].

Cost and Savings Programs for South Dakota Patients

Tresiba's list price makes cost the single largest barrier for uninsured or underinsured South Dakota patients. Four concrete options reduce that barrier.

The Novo Nordisk My$99Insulin program limits monthly cost to $99 for commercially insured patients who provide proof of a current prescription. Enrollment takes roughly 10 minutes online at the Novo Nordisk website and does not require income verification [17].

The NovoCare Patient Assistance Program provides Tresiba free of charge to uninsured patients at or below 400% of the federal poverty level (approximately $58,320 annually for a single person in 2025). Applications require proof of income, proof of U.S. residency, and a completed prescriber form [17].

GoodRx and similar discount card programs negotiate retail prices at South Dakota pharmacies to approximately $250 to $320 per FlexTouch pen (3 mL, 100 units/mL), roughly a 40% reduction from list price [14]. Discount cards cannot be combined with insurance or with Novo Nordisk manufacturer coupons.

Medicare Part D plans vary in their Tresiba tier placement. Patients who reach the catastrophic coverage threshold (out-of-pocket costs exceeding $2 to 000 in 2025 under the Inflation Reduction Act changes) pay no more than $35 per month for covered insulin products. Tresiba's coverage status depends on the specific Part D plan, making plan comparison through Medicare.gov's plan finder essential at each open enrollment period [20].

How Long Until You Receive Tresiba in South Dakota

From the first telehealth appointment to first injection, most South Dakota patients should plan for five to fourteen business days if insurance prior authorization is required, or two to four business days if paying cash or using a manufacturer savings card.

The breakdown is as follows. A telehealth visit and prescription transmission typically complete within 24 to 72 hours of booking [11]. If prior authorization is needed, the insurer has up to three business days to respond to a standard request or 72 hours for an urgent request under South Dakota insurance regulations [19]. Once approved, mail-order pharmacies ship within one to two business days with three-to-seven-day delivery to South Dakota [15]. Retail pharmacies that stock Tresiba can dispense same-day if prior authorization is already resolved.

Patients who are transferring an existing Tresiba prescription from another state can request that the new South Dakota pharmacy contact the prior pharmacy directly. South Dakota law permits prescription transfers for non-controlled substances, and the receiving pharmacist can call or fax the originating pharmacy to transfer the remaining refills [21]. Prior authorization must be re-established with the South Dakota insurer even if coverage existed in the previous state.

Transferring a Tresiba Prescription to South Dakota

Patients relocating to South Dakota with an existing Tresiba prescription from another state face two separate tasks: transferring the dispensing pharmacy record and re-establishing insurance coverage if their plan changes.

The pharmacist-to-pharmacist transfer process for a non-controlled substance like insulin degludec is governed by South Dakota Board of Pharmacy rules, which align with the National Association of Boards of Pharmacy model act [21]. The receiving pharmacy obtains the remaining refills authorized by the original prescription. If the original prescription has expired (most states allow up to one year from the date written), a new prescription from a South Dakota-licensed provider is required.

Insurance re-verification is common when a patient moves states. Even if the patient keeps the same commercial insurer, a change in the state of residence sometimes shifts the formulary tier or the prior authorization criteria applied. Calling the insurer's member services line before relocating to confirm Tresiba's coverage status in the South Dakota formulary saves time.

Patients with a continuous glucose monitor (CGM) prescription should simultaneously transfer or renew that prescription, since paired CGM-and-basal-insulin management is recommended by the Endocrine Society for all adults using basal insulin who can tolerate CGM use [9].